RASSF10 is a tumor suppressor gene located on chromosome 11.2 that plays a critical role in regulating embryonic neurogenesis and controlling cellular proliferation 1. Mechanistically, RASSF10 exhibits cell-cycle-dependent subcellular localization to centrosomes and microtubules during mitosis 1, and suppresses cancer cell growth primarily through activation of P53 signaling 2. RASSF10 induces G2/M phase cell cycle arrest, apoptosis, and can sensitize cancer cells to docetaxel chemotherapy 32. The gene likely regulates Wnt/β-catenin and MMP2 pathways 4. Epigenetic inactivation via promoter hypermethylation is the primary mechanism of RASSF10 loss in cancer. RASSF10 methylation occurs frequently in gliomas (67.5% of grade II-IV astrocytomas), breast cancer (77.8% of primary tumors), hepatocellular carcinoma (82.6%), lung cancer, and acute lymphoblastic leukemia, but rarely in normal tissues 1325. Methylation status correlates with tumor size, TNM stage, and serves as an independent prognostic factor for progression-free and overall survival 12. RASSF10 methylation status is a promising biomarker for minimal residual disease detection and docetaxel chemotherapy resistance 62.